Attached files
| file | filename |
|---|---|
| EX-32 - EX-32 - Spero Therapeutics, Inc. | spro-ex32_150.htm |
| EX-31.2 - EX-31.2 - Spero Therapeutics, Inc. | spro-ex312_6.htm |
| EX-31.1 - EX-31.1 - Spero Therapeutics, Inc. | spro-ex311_14.htm |
| EX-10.28 - EX-10.28 - Spero Therapeutics, Inc. | spro-ex1028_438.htm |
| EX-10.25 - EX-10.25 - Spero Therapeutics, Inc. | spro-ex1025_149.htm |
| EX-10.13 - EX-10.13 - Spero Therapeutics, Inc. | spro-ex1013_147.htm |
| EX-10.8 - EX-10.8 - Spero Therapeutics, Inc. | spro-ex108_148.htm |
| 10-K - 10-K - Spero Therapeutics, Inc. | spro-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-228661) and Form S-8 (Nos. 333-230283, 333-230281, 333-222060, 333-237283, and 333-241681) of Spero Therapeutics, Inc. of our report dated March 11, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 11, 2021